This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Solans-Laqué, R Articles by Vilardell-Tarres, M Search for Related Content PubMed PubMed Citation Articles by Solans-Laqué, R Articles by Vilardell-Tarres, M Social Bookmarking                   What's this?

Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes

Department of Internal Medicine, Vall d’Hebrón General Hospital, Barcelona, Spain, rsolans{at}hg.vhebron.es

C Pérez-Bocanegra

Department of Internal Medicine, Vall d’Hebrón General Hospital, Barcelona, Spain

A Salud-Salvia

Oncology Division, Vall d’Hebrón General Hospital, Barcelona, Spain

V Fonollosa-Plá

Department of Internal Medicine, Vall d’Hebrón General Hospital, Barcelona, Spain

M J Rodrigo

Biochemistry Department, Vall d’Hebrón General Hospital, Barcelona, Spain

L Armadans

Preventive Medicine, Vall d’Hebrón General Hospital, Barcelona 08035, Spain

C P Simeón-Aznar

Department of Internal Medicine, Vall d’Hebrón General Hospital, Barcelona, Spain

M Vilardell-Tarres

Department of Internal Medicine, Vall d’Hebrón General Hospital, Barcelona, Spain

Our objective was to determine the prevalence of antinuclear antibodies (ANAs) in patients with malignancies and to investigate if their presence might be related with development of musculoskeletal symptoms or paraneoplastic rheumatic syndromes. Antinuclear antibodies were determined by indirect immunofluorescenceon Hep-2 cells in 274 neoplasticpatients and in a control group of 140 age-adjusted healthy subjects. Antinuclear antibody specificities (anti-DNA and anti-ENA) were investigated in patients with rheumatological symptoms and positive ANA. Antinuclear antibodies were detected in 76 of 274 (27.7%) patients with malignancies and in nine of 140 (6.4%) healthy subjects. Twenty patients reported paraneoplasticrheumatic symptoms or syndromes. Two of them developedclinical symptoms mimicking rheumatoid arthritis (rheumatoid-likearthropathy), one systemic lupus erythematosus (lupus-like syndrome), one dermatomyositis and four cutaneous vasculitides. Musculoskeletal symptoms and paraneoplastic rheumatic symptoms and syndromes were both more frequently observed in patients with positive ANA. Antinuclear antibody specificities were found in only two cases. We can conclude that there is an increased incidence of antinuclear antibodies in malignant conditions. Musculoskeletal symptoms and rheumatic paraneoplastic symptoms and syndromes seem to be more frequent in patients with cancer-related positive ANAs. The failure to find ANA specificities (anti-ENA, anti-DNA) in patients with malignanciesand positive ANAs in our study may simply reflect molecular differences between the autoantigens involved in cancer and those characteristicallyinvolved in the systemic autoimmune diseases.

Key Words: antinuclear antibodies • malignancy • musculoskeletal symptoms • paraneoplastic syndromes

Lupus, Vol. 13, No. 3, 159-164 (2004)
DOI: 10.1191/0961203304lu521oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. G. Bouwhuis, S. Suciu, S. Collette, S. Aamdal, W. H. Kruit, L. Bastholt, U. Stierner, F. Sales, P. Patel, C. J. A. Punt, et al. Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon J Natl Cancer Inst, June 16, 2009; 101(12): 869 - 877. [Abstract] [Full Text] [PDF]

				J M Porcel, J Ordi-Ros, A Esquerda, M Vives, A B Madronero, S Bielsa, M Vilardell-Tarres, and R W Light Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis Lupus, January 1, 2007; 16(1): 25 - 27. [Abstract] [PDF]

				J. Zwerina, E. Feierl, I. Noebauer, A. Soleiman, J. S. Smolen, K. Redlich, and G. Schett Against the current--when primary pericardial disease causes rheumatic disease Rheumatology, August 1, 2006; 45(8): 1042 - 1043. [Full Text] [PDF]

				L De Rycke, D Baeten, E Kruithof, F Van den Bosch, E M Veys, and F De Keyser The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications Lupus, December 1, 2005; 14(12): 931 - 937. [Abstract] [PDF]